SCHEMBL22326769

SCHEMBL22326769

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(S)O[C@@H]2[C@H](O)[C@@H](CO)O[C@H]2n2cnc3c(N)ncnc32)[C@@H](O)[C@H]1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RNASEL Q05823 9/20 0.73
▸ ADORA1 P30542 3/20 0.73
▸ P2RY1 P47900 4/20 0.69
▸ P2RY2 P41231 3/20 0.69
▸ SMN1; SMN2 Q16637 3/20 0.69
▸ SRC P12931 2/20 0.69
▸ DNPH1 O43598 1/20 0.69
▸ PRKAB2 O43741 1/20 0.69
▸ TRPM2 O94759 1/20 0.69
▸ LDHA P00338 1/20 0.69
▸ ADRB2 P07550 1/20 0.69
▸ FBP1 P09467 1/20 0.69
▸ PRKAG1 P54619 1/20 0.69
▸ PRKAA2 P54646 1/20 0.69
▸ PDE4D Q08499 1/20 0.69
▸ KCNH2 Q12809 1/20 0.69
▸ PRKAA1 Q13131 1/20 0.69
▸ PDE3A Q14432 1/20 0.69
▸ TAS1R3 Q7RTX0 1/20 0.69
▸ TAS1R1 Q7RTX1 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020487 1.00 RNASEL (0.73) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL12963654 0.94 RNASEL (0.69) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL22326774 0.92 ADORA1 (0.70) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL22326736 0.91 RNASEL (0.62) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL18520778 0.91 RNASEL (0.62) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL18510963 0.91 RNASEL (0.62) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL13020730 0.91 P2RY1 (0.67) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL13020480 0.91 P2RY1 (0.67) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL13020484 0.91 RNASEL (0.65) RNASELADORA1P2RY1P2RY2SMN1; SMN2
SCHEMBL24113798 0.90 RNASEL (0.88) RNASEL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738074-B2 Cyclic di-nucleotide compounds as STING agonists MERCK SHARP & DOHME CORP. (US) 2020-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738074-B2 Cyclic di-nucleotide compounds as STING agonists STING1, CGAS, IFNAR1 RNASEL 555/4885ADORA1 36/4885P2RY1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback